In regard to updating pathways and guidelines, Dr Sonnad asked about the opportunity for newer, expensive immunotherapies to be included in a pre-determined pathway.
In regard to updating pathways and guidelines, Dr Sonnad asked about the opportunity for newer, expensive immunotherapies to be included in a pre-determined pathway.
Dr Nabhan said one cannot exclude a drug just because it’s expensive. It takes time to understand the collective cost of a particular drug on a patient population, and how it impacts the healthcare community, which includes payers, provider, and patient.
“Any drug that has been approved by the regulatory authorities because it had demonstrated a benefit for patients, improved survival, improved clinical benefit, etcetera, cannot be excluded from a pathway. I think it’s critical, especially when you have an abundance of evidence,” said Dr Nabhan. “You have to balance the cost versus the benefit.”
Dr Malin agreed, saying WellPoint rewards quality care. If a new therapy improves patient outcomes on the pathway, they won’t exclude it solely based on cost. Pathways, like the rest of clinical medicine, is an iterative process. Groundbreaking therapies that could change the outcomes of a large patient population, for instance, might warrant immediate regimen integration.
Dr Malin added that as evidence accumulates, therapies could be added or removed depending on their toxicity.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Accountable Care Organization Initiatives to Improve the Cost and Outcomes of Specialty Care
April 2nd 2024Engaging specialty physicians is an emerging area of focus for Medicare accountable care organizations. Enhanced data on specialist costs and outcomes are essential to addressing alignment challenges.
Read More
Covered Preventive Services at Risk: V-BID Summit Breaks Down the Braidwood v Becerra Case
March 20th 2024For more than a decade, certain high-value preventive care services have been covered at no cost to patients under the Affordable Care Act, but a current legal challenge has the coverage at risk.
Read More